

Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate at Nordic Health Summit Japan, April 23–24, 2026 in Tokyo, Japan, and ChinaBio Partnering Forum, April 28–29, 2026 in Shanghai, China. The events provide strategic platforms to advance partnering discussions with potential pharmaceutical partners and strengthen Cereno Scientific’s growing presence in key Asian markets aiming to maximize the value of its HDAC inhibitor platform and pipeline.

Cereno Scientific will participate in partnering meetings with pharmaceutical companies, investors, and industry stakeholders at both events. Nordic Health Summit Japan, organized by Business Sweden, is a high-level meeting platform designed to strengthen collaboration between Nordic life science companies and the Japanese healthcare ecosystem. ChinaBio® Partnering Forum is one of Asia’s leading life science partnering conferences, bringing together global and Chinese biopharma companies to foster cross-border collaborations.

“Expanding our presence in Asia is a strategic priority, and these events provide important opportunities to engage with potential partners in key markets such as Greater China region, Japan and South Korea,” said Sten R. Sørensen, CEO of Cereno Scientific. “We are entering these discussions with strong momentum from our CS1 and CS014 programs. We are pleased with the recently communicated data from our Expanded Access Program and view the findings as supportive of our upcoming Phase IIb plans, while also contributing to de-risking of the regulatory pathway and advancing ongoing partnering discussions.”

Cereno Scientific advances an epigenetic HDAC inhibitor platform designed to target underlying disease mechanisms central to a range of cardiopulmonary diseases driven by vascular remodeling, fibrosis, inflammation, and thrombosis. The goal is to develop disease-modifying treatments that can slow down, halt and reverse disease progression. The platform is based on small-molecule epigenetic modulators and leverages a repeatable biological mechanism with potential applicability across multiple cardiopulmonary indications. HDAC inhibitors CS1 and CS014 are positioned as potential first-in-class therapies in PAH and PH-ILD, respectively, developed as oral once-daily well-tolerated therapies with favorable safety profile.

To book a meeting with Cereno Scientific, please contact: business.development@cerenoscientific.com, or connect with the team via the event partnering platform.

For further information, please contact:

Tove Bergeholt, Head of IR & Communications
Email: tove.bergeholt@cerenoscientific.com
Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12-months treatment. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in rare thrombotic diseases.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.